Shandong Boan Biotechnology Co., Ltd. (HKG:6955)

Market Cap	1.87B -71.3%
Revenue (ttm)	720.87M -17.5%
Net Income	-111.27M
EPS	-0.19
Shares Out	622.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	346,400
Open	3.195
Previous Close	3.125
Day's Range	2.950 - 3.195
52-Week Range	2.400 - 11.200
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HKG:6955

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 690
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6955

Financial Performance

In 2025, HKG:6955's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error